Results 51 to 60 of about 13,638 (219)

Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer

, 2013
Oncolytic virotherapy - the use of viruses that specifically kill tumor cells - is an innovative and highly promising route for treating cancer. However, its therapeutic outcomes are mainly impaired by the host immune response to the viral infection.
Ferreira, Silvio C, Martins, Marcelo L, Paiva, Leticia R, Silva, Hallan S   +3 more
core   +2 more sources

A Novel Molecular Therapy Using Bioengineered Adenovirus for Human Gastrointestinal Cancer [PDF]

, 2011
Replication-selective tumor-specific viruses constitute a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Human telomerase is
Fujiwara, Toshiyoshi
core   +1 more source

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors

Viruses
NUT (nuclear-protein-in-testis) carcinoma (NC) is a highly aggressive tumor disease. Given that current treatment regimens offer a median survival of six months only, it is likely that this type of tumor requires an extended multimodal treatment approach
Stavros Sotiriadis, Julia Beil, Susanne Berchtold, Irina Smirnow, Andrea Schenk, Ulrich M. Lauer   +5 more
doaj   +1 more source

Oncolytic Virotherapy with Myxoma Virus [PDF]

Journal of Clinical Medicine, 2020
Oncolytic viruses are one of the most promising novel therapeutics for malignant cancers. They selectively infect and kill cancer cells while sparing the normal counterparts, expose cancer- specific antigens and activate the host immune system against both viral and tumor determinants.
Masmudur M. Rahman, Grant McFadden
openaire   +2 more sources

Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells [PDF]

, 2009
Replicating viruses have broad applications in biomedicine, notably in cancer virotherapy and in the design of attenuated vaccines; however, uncontrolled virus replication in vulnerable tissues can give pathology and often restricts the use of potent ...
Ryan Cawood, Hannah H. Chen, Fionnadh Carroll, Miriam Bazan-Peregrino, Nico van Rooijen, Leonard W. Seymour, Klaus Früh, TC Liu, RM Zinkernagel, M Vignuzzi, D Kirn, EJ Small, M Lagos-Quintana, S Deng, RS Pillai, TW Nilsen, M Lagos-Quintana, BD Brown, BD Brown, D Barnes, EJ Kelly, J Chang, SJ Duncan, SM Frisch, M Bazan-Peregrino, E Ylosmaki, N Mittereder, G Karber, NK Green, N Van Rooijen   +29 more
core   +3 more sources

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

Pharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Qing Ji, Yuchen Wu, Andreas Albers, Meiyu Fang, Xu Qian   +4 more
doaj   +1 more source

The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics

Pathogens
Cutaneous T-cell lymphoma (CTCL) is a devastating, potentially fatal T-lymphocyte malignancy affecting the skin. Despite all efforts, the etiology of this disease remains unknown.
Assia Angelova, Jean Rommelaere, Guy Ungerechts   +2 more
doaj   +1 more source

Myxoma Virus dsRNA Binding Protein M029  Inhibits the Type I IFN‐Induced Antiviral State in a  Highly Species‐Specific Fashion

Viruses, 2017
Myxoma virus (MYXV) is Leporipoxvirus that possesses a specific rabbit‐restricted host tropism but exhibits a much broader  cellular host range in cultured cells.
Masmudur M. Rahman, Grant McFadden
doaj   +1 more source

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma [PDF]

, 2010
A fully intact immune system would be expected to hinder the efficacy of oncolytic virotherapy by inhibiting viral replication. Simultaneously, however, it may also enhance antitumor therapy through initiation of proinflammatory, antiviral cytokine ...
Barber, G, Diaz, RM, Galivo, F, Kottke, T, Melcher, A, Thompson, J, Vile, R, Wongthida, P   +7 more
core   +1 more source

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source